XTNT Stock Analysis: Buy, Sell, or Hold?
XTNT - Xtant Medical Holdings, Inc.
$0.59
-0.02 (-2.95%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
Get Alerted When XTNT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XTNT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XTNT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: XTNT is currently trading at $0.59, which is considered oversold relative to its 30-day fair value range of $0.63 to $0.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 59.2) compared to its historical average (69.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XTNT is showing sideways momentum. The price is currently testing key support at $0.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XTNT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.50 (+153.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XTNT is showing sideways momentum. The price is currently testing key support at $0.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XTNT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.50 (+153.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.63 -
$0.75
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding XTNT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.4% below Wall St target ($1.50)
- CAUTION: 5-day price weakness (-9.3%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$0.63 -
$0.75
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.60
Resistance Level
$0.70
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
59.20
Wall Street Target
$1.50
(+153.4%)
Revenue Growth (YoY)
19.0%
Profit Margin
1.3%
Valuation Discount vs History
-5.2% cheaper
PE vs Historical
59.2 vs 69.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.2%
(market-implied from PE analysis)
1-Year Target
$0.56
(-5%)
2-Year Target
$0.53
(-10%)
3-Year Target
$0.50
(-15%)
3-Yr Target (if PE normalizes)
(PE: 59→69)
$0.59
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 59.2, Growth: -66.7%)
$0.43
(+-27%)
Base:
(SPY PE: 22.3, Growth: -66.7%)
$0.16
(-73%)
Bear:
(PE: 19.0, Growth: -66.7%)
$0.14
(-77%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (62x PE), but valuation improves significantly next year (59x PE) as earnings recover.
Trailing PE: 61.60 | Current EPS (TTM): $0.01
Bull Case
$0.68
(+15%)
Analyst growth 0.0%, PE expands to 67.8
Base Case
$0.62
(+4%)
Market implied 0.0%, PE stable at 61.6
Bear Case
$0.42
(-29%)
Severe decline -20.0%, PE contracts to 52.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 59.2 to 69.4
Stabilization Target:
$0.69
(+17.2%)
PE Expansion Potential:
+17.2%
Last updated: January 31, 2026 9:17 PM ET
Data refreshes hourly during market hours. Next update: 10:17 PM
Data refreshes hourly during market hours. Next update: 10:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XTNT showing a specific setup today?
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$374 | 54 HOLD |
Advanced XTNT Option Strategies
Professional options setups generated by AI based on today's XTNT price and gamma walls.
